Allogene raises another $120m to develop ‘off-the-shelf’ CAR-Ts
Startup biotech already raised $300m earlier this year
Richard Staines
Allogene, blood cancer, cancer, CAR T, Cellectis, Pfizer
0 Comment
Startup biotech already raised $300m earlier this year
News/ News/ News/ Oncology/ R&D/ R&D/ US
Richard Staines
Allogene, cancer, CAR T, Cellectis, Gilead, Kite Pharma
0 Comment
Belldegrun and Chang’s Allogene to take over from Pfizer in R&D deal
Gilead/ News/ News/ News/ Novartis/ Oncology/ Pfizer/ R&D/ R&D
Richard Staines
blood cancer, cancer, CAR T, Cellectis, Gilead, Novartis, Pfizer
0 Comment
US hospitals struggle to provide approved autologous therapies
Richard Staines
cancer, CAR T, Cellectis, Gilead, Juno, Novartis, R&D, safety
0 Comment
Regulator agrees to restart phase 1 trial of UCART 123
Richard Staines
blood cancer, cancer, CAR T, Cellectis, Kite, Novartis, safety
0 Comment
Richard Staines
Biotech, cancer, cancer immunotherapy, CAR T, Cellectis, Kite, Novartis, Pfizer, Servier
0 Comment
Companies hope to challenge traiblazers Novartis and Kite.
Andrew McConaghie
CAR T, Cellectis, Great Ormond Street Hospital, Pfizer, Servier
0 Comment